Pembrolizumab and Enobosarm in Treating Patients With Androgen Receptor Positive Metastatic Triple Negative Breast Cancer

ClinicalTrials.gov ID: NCT02971761

Public ClinicalTrials.gov record NCT02971761. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:27 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This phase II trial studies the side effects and how well pembrolizumab and enobosarm work in treating patients with androgen receptor positive triple negative breast cancer that has spread to other places in the body (metastatic). Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Androgen can cause the growth of breast cancer cells. Hormone therapy using enobosarm may fight breast cancer by blocking the use of androgen by the tumor cells. Giving pembrolizumab and enobosarm may work better than pembrolizumab alone in treating patients with androgen receptor positive triple negative breast cancer.

Study identification

NCT ID: NCT02971761
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: City of Hope Medical Center; Other
Enrollment: 18 participants

Conditions and interventions

Conditions

Interventions

Drug · Other · Biological

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 1, 2017 (Actual)
Primary completion: Oct 28, 2020 (Actual)
Completion: Aug 16, 2022 (Actual)
Last update posted: Feb 20, 2024

2017 – 2022

United States locations

U.S. sites: 7
U.S. states: 1
U.S. cities: 7

Facility	City	State	ZIP	Site status
City of Hope Corona	Corona	California	92879	—
City of Hope Medical Center	Duarte	California	91010	—
City of Hope Antelope Valley	Lancaster	California	93534	—
City of Hope Mission Hills	Mission Hills	California	91345	—
City of Hope Rancho Cucamonga	Rancho Cucamonga	California	91730	—
City of Hope South Pasadena	South Pasadena	California	91030	—
City of Hope West Covina	West Covina	California	91790	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT02971761, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Feb 20, 2024 · Synced Oct 27, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02971761 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →